Search Results
Sep 03, 2026, 08:55 ET AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
current developments this week include: MindWalk Holdings Corp. (Nasdaq: HYFT), Tempus AI, Inc. (Nasdaq: TEM), Schrödinger, Inc. (Nasdaq: SDGR), Twist Bioscience Corporation (Nasdaq: TWST), Absci Corporation (Nasdaq: ABSI).Forecasters size the category differently but
More news about: Equity Insider
Jul 23, 2026, 09:05 ET An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
compliance without a reverse split or dilutive financing.The broader AI-platform and computational-biology field includes Schrödinger (NASDAQ: SDGR), AbCellera Biologics (NASDAQ: ABCL), Relay Therapeutics (NASDAQ: RLAY), and Certara (NASDAQ: CERT), each pursuing its own model
More news about: USA News Group
Jul 01, 2026, 09:00 ET As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
data-and-platform direction as other public life-sciences AI names, including Tempus AI (NASDAQ: TEM), AbCellera (NASDAQ: ABCL), Schrödinger (NASDAQ: SDGR), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for MindWalk.Patenting the Moat, Not the ModelThere is
More news about: USA News Group
Jun 16, 2026, 08:45 ET The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
sector — building both the data engine and the drug pipeline — and the patient capital that strategy requires.Schrödinger, Inc. (NASDAQ: SDGR) approaches the problem from a different intellectual tradition: physics-based computational chemistry. Its software platform simulates how molecules
More news about: Equity Insider
Jan 29, 2026, 09:25 ET AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Recursion Pharmaceuticals (NASDAQ: RXRX), Tempus AI (NASDAQ: TEM), Schrodinger (NASDAQ: SDGR) and Eli Lilly (NYSE: LLY) as they bridge the gap between old-school hardware and high-fidelity digital control.
More news about: Equity Insider
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
(NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), and Schrödinger, Inc. (NASDAQ: SDGR).
More news about: Equity Insider